Natalie B. Collins

5.0k total citations · 2 hit papers
21 papers, 1.7k citations indexed

About

Natalie B. Collins is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Natalie B. Collins has authored 21 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Natalie B. Collins's work include Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (4 papers) and Neuroblastoma Research and Treatments (4 papers). Natalie B. Collins is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (4 papers) and Neuroblastoma Research and Treatments (4 papers). Natalie B. Collins collaborates with scholars based in United States, Canada and Australia. Natalie B. Collins's co-authors include W. Nicholas Haining, Robert T. Manguso, Vikram R. Juneja, Arlene H. Sharpe, Martin W. LaFleur, Gordon J. Freeman, Kathleen A. McGuire, Kevin Bi, Brian C. Miller and Kathleen B. Yates and has published in prestigious journals such as Nature, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Natalie B. Collins

20 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

2017 774 citations Robert T. Manguso, Hans W. Pope et al. Nature profile →
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

2017 612 citations Vikram R. Juneja, Kathleen A. McGuire et al. The Journal of Experimental Medicine profile →

Peers

Countries citing papers authored by Natalie B. Collins

Since Specialization

Citations

This map shows the geographic impact of Natalie B. Collins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natalie B. Collins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natalie B. Collins more than expected).

Fields of papers citing papers by Natalie B. Collins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natalie B. Collins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natalie B. Collins. The network helps show where Natalie B. Collins may publish in the future.

Co-authorship network of co-authors of Natalie B. Collins

This figure shows the co-authorship network connecting the top 25 collaborators of Natalie B. Collins. A scholar is included among the top collaborators of Natalie B. Collins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natalie B. Collins. Natalie B. Collins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors 2025 ·Pediatric Blood & Cancer ·(unknown), Sonja E. Stutzman, (unknown), (unknown), MinJae Lee, Avanthi Tayi Shah, Arhanti Sadanand, Elizabeth Sokol, Natalie B. Collins, Brian Turpin, Shoba A. Navai, (unknown), Theodore W. Laetsch, Dinesh Rakheja, Kenneth Chen, David E. Gerber, Andrew Y. Koh	0
2	Off‐label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center 2024 ·Cancer Medicine ·Ajami Gikandi, Susan Chi, Kee Kiat Yeo, Allison F. O’Neill, David S. Shulman, Steven G. DuBois, Natalie B. Collins	3
3	Abstract CT007: Phase 1/2 trial of copanlisib in combination with nivolumab for microsatellite stable (MSS) colorectal cancer (CRC) 2024 ·Cancer Research ·Eric S. Christenson, Jeremiah A. Wala, Rose Parkinson, Natalie B. Collins, Christopher Jakubowski, (unknown), Hao Wang, Won Jin Ho, Sabrina Chan, Rachel Klein, (unknown), Emma Johnson, (unknown), Jeffrey A. Meyerhardt, Benjamin L. Schlechter, Harshabad Singh, Peter K. Sorger, Marios Giannakis, Nilofer S. Azad	2
4	PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment 2022 ·Journal for ImmunoTherapy of Cancer ·Natalie B. Collins, Rose Al Abosy, Brian C. Miller, Kevin Bi, Qihong Zhao, Michael Quigley, (unknown), Kathleen B. Yates, Hans W. Pope, Robert T. Manguso, Yashaswi Shrestha, Marc H. Wadsworth, Tudor Hughes, Alex K. Shalek, Jesse S. Boehm, William C. Hahn, John G. Doench, W. Nicholas Haining	47
5	Derivation and validation of a risk classification tree for patients with synovial sarcoma 2022 ·Cancer Medicine ·Dylan V. Neel, Clement Ma, Natalie B. Collins, Jason L. Hornick, George D. Demetri, David S. Shulman	2
6	Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy 2021 ·PEDIATRICS ·Franziska Wachter, Alyaa Al‐Ibraheemi, Maria Trissal, Monica Hollowell, Steven G. DuBois, Natalie B. Collins, Alanna J. Church, Katherine A. Janeway	2
7	Phase II study of nivolumab and ipilimumab in children and young adults with INI1-negative cancers. 2021 ·Journal of Clinical Oncology ·Suzanne J. Forrest, (unknown), Cassie Kline, Thomas F. Cash, Alyssa Reddy, Gregory M. Coté, Priscilla Merriam, Jeffrey T. Czaplinski, (unknown), Steven G. DuBois, Katherine A. Janeway, Pei‐Chi Kao, Wendy B. London, Susan Chi, Natalie B. Collins	4
8	Pilot study of nivolumab in pediatric patients with hypermutant cancers. 2021 ·Journal of Clinical Oncology ·Daniel A. Morgenstern, Natalie B. Collins, Rebecca Deyell, Rina Dvir, Melissa Edwards, Cécile Faure‐Conter, Tim Hassall, (unknown), (unknown), Uri Tabori, Éric Bouffet	3
9	Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers 2020 ·Clinical Cancer Research ·Suzanne J. Forrest, Alyaa Al‐Ibraheemi, Duong Doan, Abigail Ward, Catherine Clinton, Juan Putra, (unknown), Cigall Kadoch, N. Susan, Steven G. DuBois, Patrick J. Leavey, Nicole R. LeBoeuf, Elizabeth A. Mullen, Natalie B. Collins, Alanna J. Church, Katherine A. Janeway	36
10	The use of interval‐compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor 2020 ·Pediatric Blood & Cancer ·Kevin X. Liu, Natalie B. Collins, Katie A. Greenzang, Elissa Furutani, Kevin Campbell, Andrew Groves, Elizabeth A. Mullen, Suzanne Shusterman, (unknown), Karen J. Marcus, Brent R. Weil, Christopher B. Weldon, A. Lindsay Frazier, Katherine A. Janeway, Allison F. O’Neill, Jennifer W. Mack, Steven G. DuBois, David S. Shulman	12
11	Role of Surgery in Rhabdomyosarcoma of the Head and Neck in Children 2020 ·The Laryngoscope ·Natasha D. Dombrowski, Nikolaus E. Wolter, Caroline D. Robson, Kosuke Kawai, Alexandria L. Irace, Sara O. Vargas, Karen J. Marcus, Jennifer W. Mack, Natalie B. Collins, Reza Rahbar	13
12	Binding of FANCI-FANCD2 Complex to RNA and R-Loops Stimulates Robust FANCD2 Monoubiquitination 2019 ·Cell Reports ·Zhuobin Liang, Fengshan Liang, Yaqun Teng, Xiaoyong Chen, Jingchun Liu, Simonne Longerich, Timsi Rao, Allison Green, Natalie B. Collins, Yong Xiong, Li Lan, Patrick Sung, Gary M. Kupfer	64
13	Pediatric post‐transplant hepatic kaposi sarcoma due to donor‐derived human herpesvirus 8 2019 ·Pediatric Transplantation ·Karen E. Ocwieja, Sara O. Vargas, Scott Elisofon, David S. Shulman, Christine K. Lee, Rima Fawaz, Natalie B. Collins, Khashayar Vakili, Tanvi Sharma	13
14	PI3K activated tumors evade tumor immunity by promoting an inhibitory myeloid microenvironment 2019 ·The Journal of Immunology ·Natalie B. Collins, Rose Al Abosy, Brian C. Miller, Kevin Bi, Robert T. Manguso, Kathleen B. Yates, W. Nicholas Haining	4
15	In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target breakdown → 2017 ·Nature ·Robert T. Manguso, Hans W. Pope, Margaret D. Zimmer, Flavian D. Brown, Kathleen B. Yates, Brian C. Miller, Natalie B. Collins, Kevin Bi, Martin W. LaFleur, Vikram R. Juneja, Sarah A. Weiss, Jennifer A. Lo, David E. Fisher, Diana Miao, Eliezer M. Van Allen, David E. Root, Arlene H. Sharpe, John G. Doench, W. Nicholas Haining	774
16	PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity breakdown → 2017 ·The Journal of Experimental Medicine ·Vikram R. Juneja, Kathleen A. McGuire, Robert T. Manguso, Martin W. LaFleur, Natalie B. Collins, W. Nicholas Haining, Gordon J. Freeman, Arlene H. Sharpe	612
17	Transcriptional Hallmarks Of Tumor Infiltrating Lymphocyte Responses To Melanoma 2013 ·Blood ·Natalie B. Collins, Jernej Godec, Lihua Zou, Martín C. Mihm, Gad Getz, W. Nicholas Haining	2
18	ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function 2008 ·Blood ·Natalie B. Collins, James B. Wilson, (unknown), (unknown), (unknown), Nigel J. Jones, Gary M. Kupfer	66
19	Molecular Pathogenesis of Fanconi Anemia 2005 ·International Journal of Hematology ·Natalie B. Collins, Gary M. Kupfer	21
20	A novel approach to studying the migratory morphology of embryonic mesenchymal cells 2000 ·Biology of the Cell ·Damien G. Harkin, John Bianco, Natalie B. Collins	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact